| abstract |
The present disclosure relates to erythroid cells that have been engineered to comprise a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered erythroid cells of the present disclosure are useful in degrading uric acid inside the engineered erythroid cell. The engineered erythroid cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered erythroid cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout. |